APM
CGEM icon

Avidity Partners Management’s Cullinan Oncology CGEM Stock Holding History

Avidity Partners Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-425,000
Closed -$7.11M – 68
2024
Q3 		$7.11M Sell
425,000
-1,134,826
-73% -$20.1M 0.36% 63
2024
Q2 		$27.2M Buy
+1,559,826
New +$33.2M 1.16% 36
2021
Q2 		– Sell
-707,359
Closed -$29.5M – 123
2021
Q1 		$29.5M Buy
+707,359
New +$28.7M 0.81% 44

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Avidity Partners Management's CGEM Position: Q4 2024 in Review

Avidity Partners Management sold out of Cullinan Oncology (CGEM) in Q4 2024, closing a stake of 425,000 shares — an estimated $7.11M sold.

Avidity Partners Management first reported a position in CGEM in Q1 2021 and held it in 3 quarters. The position peaked at $29.5M in Q1 2021. 146 funds tracked by Wall St. Rank hold CGEM as of Q4 2024.

  • Avidity Partners Management reported no remaining Cullinan Oncology position as of Q4 2024 after selling out during the quarter.
  • Avidity Partners Management sold 425,000 Cullinan Oncology shares in Q4 2024, an estimated $7.11M.
  • Avidity Partners Management first reported a position in Cullinan Oncology in Q1 2021 and held it in 3 quarters.
  • Avidity Partners Management's Cullinan Oncology position peaked at $29.5M in Q1 2021.
  • 146 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2024.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.